ESTRO 2024 - Abstract Book

S2507

Clinical - Urology

ESTRO 2024

Results:

Between 2019 and 2023 30 patients were recruited (table). Median follow up was 21.3 months. Median time to PSA progression was 21.1 months (Arm 1) vs 6.5 months (Arm 2, p=0.05, figure).

In Arm 1, 17 of 18 patients had immediate aRT and in Arm 2, 5/12 had aRT after progression.

Table: Baseline patient characteristics

Arm

1

Arm 2 (n=12) All patients (n=30)

(n=18)

Median

age

at

69.5

71.5

70.5

randomization (years)

Median time from primary treatment (months)

55.5

82.5

58.5

Initial NCCN risk

Low

or

2 (11.2%)

5 (41.7%)

7 (24.3%)

intermediate

high

2 (11.1%)

4 (33.3%)

6 (20%)

very high

10 (50.6%) 2 (16.7%)

12 (40%) 5 (16.7%)

N+ / M+

4 (22.2%)

1 (8.3%)

Initial treatment

Radical prostatectomy Postop. RT (+ pelvic RT) Primary RT (+ pelvic RT)

15

10

25

7/15 (5/7) 5/10 (3/5)

12/25 (8/12)

3 (1/3)

2 (1/2)

5 (2/5)

Time on ADT (months)

33

33.5

33.5

Patients with ADT / +ARPI

18 / 4

12 / 4

30 / 8

Lesions per patient

1 2 3 4 5

9 1 3 2 3 6 8 4

6 3 1 2 0 5 6 1

15

4 4 4 3

Type of lesions

Lymph node

11 14

Bone

Ln and bone

5

Figure: Kaplan-Meier estimator of time to PSA progression for Arm 1+2